The HER2 gene mutation is best known for the test for breast cancer and now the mutations are proving to show some target relief with treating gastric cancer. The study is finding that a combination targeted treatment with 2 drugs is having success...
Filed under: Medically Related, Pharma/FDA News, health insurance, Cancer, Oncology, Breast Cancer, United HealthCare, Therapy, UCLA Jonsson Cancer Center, reasearch and development, gastric cancer, targets, herception, Tykerb, HER2